Acquired Pre-Approval Rare Disease Asset in Bankruptcy Auction

PTC Therapeutics (PTCT) acquired ST-920, a Fabry disease gene therapy from Sangamo Therapeutics (SGMO), for an upfront payment of $111 million and up to $100 million in regulatory milestone payments. The total transaction value is up to $211 million. In a Chapter 11 asset sale overseen by the court, PTC outbid Astellas Pharma (4503·ALPMY) and TerSera Therapeutics. Considering that the initial stalking horse proposal had an upfront payment of $25 million, the cash value significantly increased during the auction process. However, PTC saves on the cost and time of directly developing the therapy from the late-stage clinical trials. By combining assets that are close to rare disease approval and commercialization, PTC's move is more of a revenue-based expansion than a simple pipeline expansion.

Mechanism and Clinical/Regulatory Status of ST-920

ST-920, with the development code before the brand name was assigned, and the generic name is isaralgagene sivaparvovec, is designed to deliver the normal GLA gene using a liver-targeted recombinant AAV2/6 vector, enabling sustained production of the alpha-galactosidase A enzyme. In the Phase 1/2 STAAR study, which enrolled 32 adult patients, the average annualized eGFR slope at 52 weeks was 1.965 mL/min/1.73m², with a 95% confidence interval of -0.153 to 4.083. The FDA agreed to use this renal function indicator as an intermediate clinical endpoint for accelerated approval and indicated that the 2-year eGFR data could be used as evidence for full approval. ST-920 has received FDA Orphan Drug, Fast Track, and RMAT designations, and EMA Orphan Drug and PRIME designations, but has not yet reached the approval or advisory committee review stage.

BLA Completion and Approval Milestones are Key Catalysts

Sangamo initiated a rolling BLA in December 2025 and submitted the non-clinical and clinical modules. The PMA for the antibody screening companion diagnostic was also received by the FDA's device center. PTC plans to complete the application, including the CMC module, in the fourth quarter of 2026 and pursue U.S. accelerated approval and launch in 2027. The payment structure includes an upfront payment of $111 million upon closing, $80 million upon FDA accelerated approval, and $20 million upon full approval, with no royalties or equity investments. Therefore, the short-term value depends on the completion of manufacturing and quality data and the acceptance of the BLA, while the medium- to long-term value depends on the confirmation of clinical efficacy through 2-year renal function data.

Differentiation with a Single Dose in a $2.3 Billion Market

In 2025, the global Fabry disease treatment market is estimated at approximately $2.3 billion, with Sanofi's Fabrazyme and agalsidase beta accounting for €1.019 billion in sales in 2025. The FDA approved Fabrazyme on April 24, 2003, Amicus Therapeutics' oral chaperone galafold and migalastat on August 10, 2018, and Chiesi and Protalix BioTherapeutics' Elfabrio and pegunigalsidase alfa on May 9, 2023. These standard treatments require repeated intravenous infusions or GLA variants with treatment response, while ST-920 aims for a single dose and sustained enzyme expression. ST-920 is ahead of competing gene therapy candidates 4D Molecular Therapeutics' 4D-310 and Freeline's FLT190 in the regulatory process, allowing it to target the first Fabry disease gene therapy. However, AAV antibody screening and long-term safety monitoring will determine the actual market penetration.